{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:26:23Z","timestamp":1786422383930,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41375-025-02852-8","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:34:28Z","timestamp":1769171668000},"page":"587-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-4151","authenticated-orcid":false,"given":"Vivian G.","family":"Oehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8067-2581","authenticated-orcid":false,"given":"Olga","family":"Sala-Torra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1954-9414","authenticated-orcid":false,"given":"Neta","family":"Gilderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Beppu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0006-5311","authenticated-orcid":false,"given":"David W.","family":"Woolston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Namaganda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rynning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s Garc\u00eda","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Towlerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Voutsinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-4816","authenticated-orcid":false,"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6799-2022","authenticated-orcid":false,"given":"Cecilia C. S.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2852_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"2852_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.580759","volume":"10","author":"Q Lin","year":"2020","unstructured":"Lin Q, Mao L, Shao L, Zhu L, Han Q, Zhu H, et al. Global, regional, and national burden of chronic myeloid leukemia, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Front Oncol. 2020;10:580759.","journal-title":"Front Oncol"},{"key":"2852_CR3","doi-asserted-by":"crossref","unstructured":"Morgan J, DeBoer RJ, Bigirimana JB, Nguyen C, Ruhangaza D, Paciorek A, et al. A ten-year experience of treating chronic myeloid leukemia in rural Rwanda: outcomes and insights for a changing landscape. JCO Glob Oncol. 2022;8:e2200131.","DOI":"10.1200\/GO.22.00131"},{"key":"2852_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-022-00686-0","volume":"18","author":"M Matsuzaki","year":"2023","unstructured":"Matsuzaki M, Annamalay A, Garcia-Gonzalez P, Radich J. CML outcomes and care delivery during the COVID-19 pandemic in low- and middle-income countries. Curr Hematol Malig Rep. 2023;18:1\u20137.","journal-title":"Curr Hematol Malig Rep"},{"key":"2852_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100257","volume":"19","author":"CA Umeh","year":"2020","unstructured":"Umeh CA, Garcia-Gonzalez P, Tremblay D, Laing R. The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: the Glivec International Patient Assistance Program (GIPAP). EClinicalMedicine. 2020;19:100257.","journal-title":"EClinicalMedicine"},{"key":"2852_CR6","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood-2015-12-689059","volume":"127","author":"O Sala Torra","year":"2016","unstructured":"Sala Torra O, Beppu L, Smith JL, Welden L, Georgievski J, Gupta K, et al. Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots. Blood. 2016;127:2773\u20134.","journal-title":"Blood"},{"key":"2852_CR7","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41375-024-02285-9","volume":"38","author":"O Sala-Torra","year":"2024","unstructured":"Sala-Torra O, Beppu L, Wu Q, Welch E, Berthier E, Radich JP, et al. Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients. Leukemia. 2024;38:1822\u20134.","journal-title":"Leukemia"},{"key":"2852_CR8","doi-asserted-by":"crossref","unstructured":"Malsagova K, Kopylov A, Stepanov A, Butkova T, Izotov A, Kaysheva A. Dried blood spot in laboratory: directions and prospects. Diagnostics. 2020;10:248.","DOI":"10.3390\/diagnostics10040248"},{"key":"2852_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00742-1","volume":"12","author":"A Bidikian","year":"2022","unstructured":"Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, et al. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022;12:144.","journal-title":"Blood Cancer J"},{"key":"2852_CR10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","volume":"33","author":"S Branford","year":"2019","unstructured":"Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33:1835\u201350.","journal-title":"Leukemia"},{"key":"2852_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23097-w","volume":"12","author":"Y Ochi","year":"2021","unstructured":"Ochi Y, Yoshida K, Huang YJ, Kuo MC, Nannya Y, Sasaki K, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun. 2021;12:2833.","journal-title":"Nat Commun"},{"key":"2852_CR12","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","volume":"36","author":"L Schonfeld","year":"2022","unstructured":"Schonfeld L, Rinke J, Hinze A, Nagel SN, Schafer V, Schenk T, et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022;36:2242\u20139.","journal-title":"Leukemia"},{"key":"2852_CR13","first-page":"2380","volume":"108","author":"N Shanmuganathan","year":"2023","unstructured":"Shanmuganathan N, Wadham C, Shahrin N, Feng J, Thomson D, Wang P, et al. Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica. 2023;108:2380\u201395.","journal-title":"Haematologica"},{"key":"2852_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2019002969","volume":"135","author":"S Soverini","year":"2020","unstructured":"Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood. 2020;135:534\u201341.","journal-title":"Blood"},{"key":"2852_CR15","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208\u201315.","journal-title":"Blood"},{"key":"2852_CR16","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","volume":"35","author":"C Kopanos","year":"2019","unstructured":"Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35:1978\u201380.","journal-title":"Bioinformatics"},{"key":"2852_CR17","doi-asserted-by":"crossref","unstructured":"Yeung CCS, Narava SK, Chang TC, Saeed M, Aicher L, Beppu LW, et al. Analytical performance of the NCI-myeloMATCH Assay: a rapid turnaround genomic profiling assay for myeloid disorders. J Mol Diagn. 2025;27:783\u201395.","DOI":"10.1016\/j.jmoldx.2025.05.001"},{"key":"2852_CR18","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41375-018-0193-y","volume":"32","author":"MO Alberti","year":"2018","unstructured":"Alberti MO, Srivatsan SN, Shao J, McNulty SN, Chang GS, Miller CA, et al. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. Leukemia. 2018;32:1874\u20138.","journal-title":"Leukemia"},{"key":"2852_CR19","doi-asserted-by":"publisher","first-page":"e0229352","DOI":"10.1371\/journal.pone.0229352","volume":"15","author":"P Sok","year":"2020","unstructured":"Sok P, Lupo PJ, Richard MA, Rabin KR, Ehli EA, Kallsen NA, et al. Utilization of archived neonatal dried blood spots for genome-wide genotyping. PLoS ONE. 2020;15:e0229352.","journal-title":"PLoS ONE"},{"key":"2852_CR20","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia Version 1. 2026\u2014July 16, 2025. Plymouth Meeting: National Comprehensive Cancer Network."},{"key":"2852_CR21","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"2852_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","volume":"129","author":"T Kim","year":"2017","unstructured":"Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129:38\u201347.","journal-title":"Blood"},{"key":"2852_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","volume":"35","author":"S Adnan Awad","year":"2021","unstructured":"Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021;35:1087\u201399.","journal-title":"Leukemia"},{"key":"2852_CR24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","volume":"132","author":"S Branford","year":"2018","unstructured":"Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132:948\u201361.","journal-title":"Blood"},{"key":"2852_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1182\/blood-2024-199899","volume":"144","author":"N Shanmuganathan","year":"2024","unstructured":"Shanmuganathan N, Wadham C, Yeung DT, Shahrin N, Fernandes A, Maqsood M, et al. Strong association between cancer gene variants at diagnosis, especially ASXL1, and emergence of kinase domain mutation-driven resistance in CML patients despite frontline treatment with more potent BCR::ABL1 inhibitors. Blood. 2024;144:991 2024.","journal-title":"Blood"},{"key":"2852_CR26","doi-asserted-by":"crossref","unstructured":"Shanmuganathan N, Yeung DT, Wadham C, Fernandes A, Maqsood M, Shahrin N, et al. Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Blood. 2025;146:2821\u201332.","DOI":"10.1182\/blood.2025030259"},{"key":"2852_CR27","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366:eaan4673.","DOI":"10.1126\/science.aan4673"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02852-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:38:12Z","timestamp":1772609892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02852-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2852"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02852-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Oehler has received research funding from Novartis, Ascentage Pharma, Terns Pharma, and Pfizer, and honoraria from Takeda. Dr. Yeung has received research funding in the form of reagent donations from Archer. Dr. Radich has received advisory honoraria from Thermo Fisher and Novartis. Jennifer Rynning and Ines Garcia-Gonzalez represent The Max Foundation, which receives in-kind donations of medicines and diagnostics for programs, as well as financial support from Novartis, Takeda, Bristol Myers Squibb, BeOne, Pfizer, Eli Lilly, Incyte, Cepheid and BD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}